324 related articles for article (PubMed ID: 37407724)
1. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease.
Vachliotis ID; Polyzos SA
Curr Obes Rep; 2023 Sep; 12(3):191-206. PubMed ID: 37407724
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
3. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.
Sharma M; Mitnala S; Vishnubhotla RK; Mukherjee R; Reddy DN; Rao PN
J Clin Exp Hepatol; 2015 Jun; 5(2):147-58. PubMed ID: 26155043
[TBL] [Abstract][Full Text] [Related]
4. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
[TBL] [Abstract][Full Text] [Related]
5. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
6. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
7. Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
Vachliotis ID; Valsamidis I; Polyzos SA
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958479
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
Potoupni V; Georgiadou M; Chatzigriva E; Polychronidou G; Markou E; Zapantis Gakis C; Filimidou I; Karagianni M; Anastasilakis D; Evripidou K; Ftergioti A; Togkaridou M; Tsaftaridis N; Apostolopoulos A; Polyzos SA
J Gastroenterol Hepatol; 2021 Nov; 36(11):3002-3014. PubMed ID: 34289181
[TBL] [Abstract][Full Text] [Related]
9. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
10. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
[TBL] [Abstract][Full Text] [Related]
13. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
14. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
[TBL] [Abstract][Full Text] [Related]
15. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
16. Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort.
Tang KT; Dufour JF; Chen PH; Hernaez R; Hutfless S
BMJ Open Gastroenterol; 2020; 7(1):e000349. PubMed ID: 32377366
[TBL] [Abstract][Full Text] [Related]
17. Selenium and selenoprotein P in nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Goulas A; Duntas L
Hormones (Athens); 2020 Mar; 19(1):61-72. PubMed ID: 31493247
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
19. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
20. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
